Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2024 · 10-Q
Revenue$163.00K$163.00K+50.9% vs Q2 2023 Net Income-$11.78M-$11.78MN/M vs Q2 2023 EPS Diluted-$0.26-$0.26N/M vs Q2 2023 Operating Income-$12,545,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,230,000N/M Margins · derivedOperating margin-7696.3%+3607.4 pt vs Q2 2023
Net margin-7225.8%+3098.3 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end